{
    "nct_id": "NCT03274492",
    "official_title": "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma",
    "inclusion_criteria": "* Previously untreated participants with cluster of differentiation 20 (CD20)-positive DLBCL, including one of the following diagnoses by 2016 World Health Organization (WHO) classification of lymphoid neoplasms: DLBCL, not otherwise specified (NOS) including germinal center B-cell type, activated B-cell type; T-cell/histiocyte-rich large B-cell lymphoma; Epstein-Barr virus-positive DLBCL, NOS; anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma; human herpesvirus-8 (HHV8)-positive DLBCL, NOS; High-grade B-cell lymphoma with MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements (double-hit or triple-hit lymphoma); High-grade B-cell lymphoma, NOS\n* Availability of archival or freshly collected tumor tissue before study enrolment\n* International Prognostic Index (IPI) score of 2-5\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2\n* Life expectancy greater than or equal to (>/=)12 months\n* Left ventricular ejection fraction (LVEF) >/= 50 percent (%) on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)\n* Adequate hematologic function\n* Female participants: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and refrain from donating eggs.\n* Male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom and agreement to refrain from donating sperm.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products\n* Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines\n* Prior organ transplantation\n* Current Grade greater than (>) 1 peripheral neuropathy by clinical examination\n* Demyelinating form of Charcot-Marie-Tooth disease\n* History of indolent lymphoma\n* History of follicular lymphoma grade 3B\n* B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma (grey-zone lymphoma)\n* Primary mediastinal (thymic) large B-cell lymphoma\n* Burkitt lymphoma\n* Prior treatment with cytotoxic drugs within 5 years of screening for any condition (example [e.g.], cancer, rheumatoid arthritis) or prior use of any anti-CD20 antibody\n* Prior use of any monoclonal antibody within 3 months of the start of Cycle 1\n* Prior therapy for DLBCL, with the exception of nodal biopsy\n* Corticosteroid use >30 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control\n* Participants with central nervous system (CNS) lymphoma (primary or secondary involvement), primary effusion DLBCL, and primary cutaneous DLBCL\n* Vaccination with live vaccines within 28 days prior to the start of Cycle 1\n* Any investigational therapy within 28 days prior to the start of Cycle 1\n* History of other malignancy that could affect compliance with the protocol or interpretation of results\n* Evidence of significant, uncontrolled, concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or pulmonary disease\n* Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis\n* History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or significant infections within 2 weeks before the start of Cycle 1\n* Clinically significant liver disease, including active viral or other hepatitis, current alcohol abuse, or cirrhosis\n* Prior radiotherapy to the mediastinal/pericardial region\n* Participants with suspected active or latent tuberculosis\n* Positive test results for chronic hepatitis B and hepatitis C infection\n* Known history of human immunodeficiency virus (HIV) seropositive status\n* Positive results for the human T-lymphotrophic 1 virus (HTLV-1)\n* Participants with a history of progressive multifocal leukoencephalopathy",
    "miscellaneous_criteria": ""
}